De PIC De PIC'SS normen en hun normen en hun integratie in de Belgische integratie in de Belgische wetgeving wetgeving LLudo Willems d Will Thomas De Rijdt 7 juni 2011
UZ Leuven 1
I h d Inhoud • Een kleine toelichting bij … – Belgische Wetgeving en ‘1885’ B l i h W t i ‘1885’ – ‘PIC’s’ normen
• Betekenis voor Belgische ziekenhuisfarmacie Betekenis voor Belgische ziekenhuisfarmacie
• Capita selecta uit ‘PIC’s’ normen i l i ‘ ’’ 2
www.ejustice.just.fgov.be/wet/wet.htm (gecoördineerde wetteksten)
3
K i klijk B l it 1885 Koninklijk Besluit 1885 31 MEI 1885. ‐ Koninklijk besluit houdende g goedkeuring der nieuwe onderrichtingen voor de g g geneesheren, de apothekers en de drogisten Publicatie : 19‐06‐1885 Originele tekst alleen in het Frans gepubliceerd Article 1. Nul ne peut exercer dans le royaume la profession de docteur en médecine, chirurgie et accouchements, de pharmacien ou de droguiste, s ou de droguiste s'ilil n n'aa obtenu son grade obtenu son grade conformément à la loi et s'il n'a pas fait viser son diplôme par la commission médicale de la province où il fixe sa résidence. (L i d 12 (Loi du 12 mars 1818, et du 20 mai 1876. ‐ 1818 t d 20 i 1876 Arrêtés royaux des A êté d 31 mai 1880 et 30 décembre 1884.) 4
V 1885 Van 1885 naar 201X 201X FOD Volksgezondheid DG3 – 2003: Vraag aan Belgische Vereniging van Ziekenhuisapothekers om bemerkingen bij nieuwe versie 1885 te formuleren – Antwoord BVZA: beoefening van de Antwoord BVZA: beoefening van de farmacie in een voor het publiek toegankelijke apotheek is verschillend van toegankelijke apotheek is verschillend van deze in een ziekenhuis 5
V 1885 Van 1885 naar 201X 201X • Vanaf 2004: naar twee KB’s – ‘Koninklijk besluit voor de open apotheken’
Artikel 1. Voor de toepassing van dit besluit moet worden verstaan onder : – KB ziekenhuisapotheek KB ziekenhuisapotheek 1° « Officina‐apotheek », hierna « apotheek » genaamd : de lokalen die bestemd zijn voor de bereiding, het ontvangen, de bewaring en de aflevering van geneesmiddelen de aflevering van geneesmiddelen … indien de apotheek opengesteld is voor het publiek 2° « Apotheker van een voor het publiek opengestelde apotheek », hierna « apotheker » genaamd : 6
V 1885 Van 1885 naar 201X 201X • Vanaf 2004: naar twee KB’s – ‘Koninklijk besluit voor de ziekenhuisapotheek’ • Koninklijk besluit houdende onderrichtingen voor j g ziekenhuisapothekers werkzaam in ziekenhuisapotheken en geneesmiddelendepots in verzorgingsinstellingen
• Publicatie?
7
Koninklijk besluit … voor j ziekenhuisapothekers … • Koninklijk besluit – Basis: KB voor open apotheken Basis: KB voor open apotheken
• Bijlagen – FFarmaceutische zorg ti h – GMP voor ziekenhuisapotheken bij bereidingen • Vaste orale vormen • Vloeistoffen, zalven en crèmes • Steriele en aseptische bereidingen • Potentieel toxische stoffen • Radiofarmaca
8
W Waarom GMP in ziekenhuizen? GMP i i k h i ?
Kwaliteit
K lit it Kwaliteit
Kwaliteit
Risico
Risico
Risico
B Bezorgdheid dh id
B Bezorgdheid dh id
B Bezorgdheid dh id
Kwaliteitsgarantie en Patiëntveiligheid Kwaliteitsgarantie en Patiëntveiligheid OVERAL voor ALLE patiënten ALTIJD
9
G d Manufacturing Good M f t i Practices P ti (GMP) • Kwaliteitsborgingssysteem voor de farmaceutische industrie cosmetische industrie en voedingsindustrie industrie, cosmetische industrie en voedingsindustrie • Controle op en documentatie van ALLE stappen in productieproces i p v enkel eindproduct productieproces i.p.v. enkel eindproduct
10
Pi i Principes GMP GMP Alle startproducten voldoen aan specificaties Alle procedures zijn vastgelegd Alle personeel is gekwalificeerd en getraind Alle personeel is gekwalificeerd en getraind Alle ruimten en apparaten pp zijn specifiek j p ontworpen en worden gecontroleerd • Alle verantwoordelijkheden en taken zijn vastgelegd (incl. eindverantwoordelijkheid) vastgelegd (incl. eindverantwoordelijkheid) • • • •
11
PIC PIC/S PIC – • • • • •
Pharmaceutical Inspection Convention Pharmaceutical Inspection Co‐operation Scheme 37 landen (binnen en buiten Europa) S Samenwerking tussen Farmaceutische inspecties ki F i h i i GMP adviezen aanvaard door EU GMP adviezen aanvaard door EU
• www.picscheme.org 12
‘PIC/S’ • Standaarden voor goede farmaceutische praktijk ktijk – GMP GUIDE (PART I: BASIC REQUIREMENTS FOR MEDICINAL PRODUCTS) – GMP GUIDE (PART II: BASIC REQUIREMENTS FOR ACTIVE ( Q PHARMACEUTICAL INGREDIENTS) – GMP GUIDE FOR BLOOD ESTABLISHMENTS GMP GUIDE FOR BLOOD ESTABLISHMENTS – ISOLATORS USED FOR ASEPTIC PROCESSING AND STERILITY TESTING –… 13
‘PIC/S’ ‘PIC/S’ voor ziekenhuizen i k h i • PE 010‐3 (okt 2008) GUIDE TO GOOD PRACTICES FOR THE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS • www.picscheme.org h All publications – miscellaneous All publications miscellaneous – documents for inspectors documents for inspectors
14
‘PIC/S’ ‘PIC/S’ voor ziekenhuizen i k h i • Deel 1
Basis B i GMP guide for industry (PE 009)
– Definities – Kwaliteitsborgingssysteem – Vereisten met betrekking tot g • • • • •
Personeel, gebouwen en uitrusting Documentatie Productie Kwaliteitscontrole g, g, g p g, Uitbesteding, klachtenbehandeling, terugroeping, zelfaudit
• Deel 2 – Bijlage 1: richtlijnen voor steriele bereidingen j g j g – Bijlage 2: richtlijnen voor bereiding van niet steriele vloeistoffen, zalven en crèmes. 15
‘PIC/S’ i ‘PIC/S’ in realiteit lit it • Architectuur – Aangepaste ruimten – Luchtzuivering en luchtverversing
• Apparaten – Weegschalen, verwarmingselementen, … – LAF kasten/ Isolatoren voor steriele bereidingen – …
• Procedures – – – –
Protocols Activiteiten strikt volgens protocols Documentatie bereidingg Training
16
B idi Bereidingen in ziekenhuis en ‘PIC/S’ i i k h i ‘PIC/S’ • Bereidingen ‘de novo’ – Capsules p – Vloeistoffen – Injecteerbare vloeistoffen j
• Eenheidsdosisverpakking to use injectables • Ready to use – – – –
Potentieel toxische stoffen Parenterale voedingg Antibiotica …
• Radiofarmaca 17
K t ij ‘PIC/S’ Kostprijs ‘PIC/S’ • Architectuur – Capaciteit C it it – Verbouwing<‐> Nieuwbouw – Inbouwmodule steriele ruimte
• Apparaten – Weegschalen, …, software, … – LAF kasten: nieuw <‐> aanwezig
• Procedures en uitvoering Procedures en uitvoering – Arbeidstijd Ï (Werkvolume Ï en werksnelheid Ð) – Gebruiksgoederen (bv kledij) 18
M Mogelijkheid lijkh id • Insourcing‐Outsourcing – Samenwerking tussen ziekenhuizen – Voorzien in wetgeving (KB 19 okt Voorzien in wetgeving (KB 19 okt 1978) – Capaciteit Ï Ï ‐> kostprijs bouw Ï
19
V Vermijden van negatieve situaties ijd ti it ti • • • •
Toepassen zorgvuldigheidsprincipe België mee op internationaal niveau België mee op internationaal niveau Houdbaarheid aseptische bereiding >24 uur (Æ GMP) Vergoedbaarheid Vergoedbaarheid – Cytostatica per mg ? – Forfaitarisatie ?
• Steeds conformiteit van ALLE bereidingen • Waarborg voor patiëntveiligheid Waarborg voor patiëntveiligheid • Farmaceutische inspectie = internationale aangelegenheid Æ geen goedkeuring, geen activiteit 20
Zi k h i Ziekenhuisapothekers en PIC/S th k PIC/S Belgische Vereniging van Ziekenhuisapothekers – belang van kwaliteit van activiteiten – belang van conformiteit van afgeleverd product – implementatie over bepaalde periode – indien nodig concentratie van activiteiten i di di i i i i – bewust van kostprijs implementatie GMP 21
Zi k h i f Ziekenhuisfarmacie i • Jaren negentig – KB KB 4 MAART 1991. 4 MAART 1991 ‐ Koninklijk besluit houdende Koninklijk besluit houdende vaststelling van de normen waaraan een ziekenhuisapotheek moet voldoen om te worden erkend – Ziekenhuisapothekers aan de klaagmuur
• 2011 – Ziekenhuisapothekers zeer dynamisch p y • • • •
Leidinggevende rol in MFC en CMM Lid van directiecomité Klinische farmacie … 22
C t t ti i h t Cytostatica in het verleden l d 1970 Letter to the Editor van het tijdschrift Pediatrics To the Editor: ... As a hematology resident, I have to give 4‐6 injections with antineoplastic drugs daily. These drugs are well known to be cytotoxic drugs daily These drugs are well known to be cytotoxic and I am distressed to find no published report on the hazards of handling such drugs. Is skin contact unable to bring about toxic effects? Editor's note: Dr Ng is probably correct that there is insufficient evidence of reported case of Dr. Ng is probably correct that there is insufficient evidence of reported case of contact dermatitis ... . However, nitrogen mustard is well known to cause a vesicant effect. With regard to systemic toxicity, this would be expected to be extremely small. I know of no reported occurrence of systemic toxicity due to trivial skin contamination. 23
C t t ti Cytostatica actueel t l 2011 • Alle cytostatica worden bereid in ziekenhuisapotheek Eerste robots verschijnen in Belgische ziekenhuizen • Eerste robots verschijnen in Belgische ziekenhuizen
24
Hoe zal het verder gaan g voor de ziekenhuisfarmacie? • FAGG in samenwerking met BVZA – Verfijning Koninklijk besluit basistekst j g j – Bijlagen Bereidingen • Werkgroep farmacopeecommissie • Elementen van andere teksten van PIC’s ? • Elementen van USP Chapter 797 ? – Pharmaceutical Ph i l Compounding—Sterile C di S il Preparations P i
• Definitief KB – Datum publicatie ? D t bli ti ? – Datum van in voege treden ?
• Werkelijkheid in ziekenhuizen W k lijkh id i i k h i – Aparte erkenning voor de verschillende modules – Nog alle bereidingen in alle ziekenhuisapotheken? ll b d ll k h h k ? 25
GUIDE TO GOOD PRACTICES FOR GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS GENERAL PART
26
G General Principles lP i i l • In order to protect public health, medicinal products should be of high quality, safe and effective • They should be prepared in such a way that they are fit for their intended purpose and that their quality consistently complies with the defined requirements • To achieve this objective reliably, there should be a comprehensively designed and correctly implemented h l d d d l l d quality assurance system, incorporating the principles of Good Preparation Practices as described in this of Good Preparation Practices as described in this Guide • The quality assurance system should be documented The quality assurance system should be documented and its effectiveness should be monitored 27
P Personnel and Equipment l dE i t • It should be guaranteed that no risk of contamination exists, either for exists either for personnel or products • Dedicated Dedicated rooms should be provided for rooms should be provided for hazardous products, e.g. cytostatics, penicillins biologicals penicillins, biologicals, radiopharmaceuticals, blood products
28
D Documentation t ti • Good documentation on paper or in electronic form constitutes an essential part of the quality form constitutes an essential part of the quality assurance system • In order to establish product specific specifications, instructions and procedures, p , p , a pharmaceutical assessment of therapeutic rationale safety data toxicity rationale, safety data, toxicity, biopharmaceutical aspects, stability and product design should be carried out before product design should be carried out, before preparation takes place 29
P d ti Production • Production should be performed by trained personnel trained personnel • Th The risk potential for health damage in case of ik i lf h l hd i f failures (e.g. quality defects) varies with diff different types of products and should f d d h ld therefore be assessed and documented by an appropriately competent person i l • The date of the first opening should be indicated for starting materials with a short in‐ p y use expiry date 30
P d ti Production • Before any processing operation is started, it is important to ensure (and document) that the work important to ensure (and document) that the work area and the equipment are clean and free from any … products d not required for the current operation … i df h i g g y y • Packaging material may only be used if suitable for the particular purpose … sufficient protection against external influences and possible against external influences and possible contamination • Labels b l should comply with national legislation h ld l h i ll i l i 31
Returned products Returned products • Dispensed products that have been returned … , should be destroyed unless there is no should be destroyed unless there is no doubt their quality is satisfactory. • They may exceptionally be considered for reprocessing or recovery only after they have p g y y y been critically assessed under the responsibility of the Responsible Person in responsibility of the Responsible Person in accordance with a written procedure. • Any action taken should be appropriately i k h ld b l recorded 32
R l Release • The Responsible Person is ultimately responsible for the quality of the medicinal products prepared and the quality of the medicinal products prepared and released • The actual release can be delegated to another appropriately competent person (i.e. Releasing pp p y p p ( g Officer)
33
O t Outsourcing i Depending on the local situation and on national legislation the work contracted out national legislation, the work contracted out by a healthcare establishment may include activities, which are directly involved with preparation, such as processing, packaging preparation, such as processing, packaging or quality control, but also services, which are not directly involved with preparation are not directly involved with preparation, … Services: ‐ maintenance of the air handling system, … ‐ handling of waste, … ‐ environmental monitoring services, … 34
Q lit Quality problems bl • Errors, defects, complaints and other signs i di ti indicating quality problems should be lit bl h ld b g pp p investigated. Appropriate measures should be in place to ensure that effective remedial action is taken The source and content of action is taken. The source and content of deficiencies, remedial measures taken and tests performed should be documented in writing and added to the preparation record writing and added to the preparation record. 35
GUIDE TO GOOD PRACTICES FOR GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS GUIDELINES ON THE STANDARDS REQUIRED FOR THE STERILE REQUIRED FOR THE STERILE PREPARATION OF MEDICINAL PRODUCTS
36
I t d ti Introduction • The sterile preparation of medicinal products includes: – The preparation of terminally sterilized products – The aseptic preparation of products The aseptic preparation of products
• Sterile preparations are considered to be high risk category products t d t • For individual product types examples of their more specific risk factors are: – Cytotoxics and radiopharmaceuticals (high level of hazard) – Total parenteral nutrition solutions (complexity) – Epidurals and cardioplegia solutions (microbial contamination) 37
P Personnel l (definitions) Responsible Person Responsible Person (Qualified Person) … who is ultimatelyy responsible p for all aspects p of the p preparation p of medicinal products including the release of these items. This person must have sufficient scientific and technical education and experience to perform this duty.
Releasing Officer … who releases the prepared medicinal products. This person may be the Responsible Person.
Production Supervisor … responsible for supervision should be in the department where the production takes place. He/she should be aware of what is going on …
Staff (pharmacists and pharm. technicians) … competent personnel to carry out all the tasks. Individual responsibilities should be documented and clearly understood …. All personnel should be aware of the principles p c p es o of Good Preparation epa at o Practice act ce … Personnel e so e sshould ou d receive ece e initial t a aand d continuing training, … 38
P Personnel l • Before undertaking sterile work, all staff should be appropriately trained and have their competence appropriately trained and have their competence assessed • Special requirements for aseptic preparation Special requirements for aseptic preparation activities: SSupervisory personnel within the aseptic preparation i l ithi th ti ti department should have an understanding of clean area and clean air device technology together with a thorough and clean air device technology together with a thorough knowledge of all the particular design features in their department e.g. ventilation systems, position and grade of p g y ,p g HEPA filters, type of work station, isolator design etc
39
E i Equipment t • Special requirements for aseptic preparation activities: – After washing, components should be handled in at least a grade D environment. Handling of sterile starting d D i t H dli f t il t ti materials and components, …, should be done in a grade A environment. i t – Handling and filling of aseptically prepared products (open and closed) should be performed … in a laminar flow d l d) h ld b f d i l i fl cabinet (LFC) or a positive pressure pharmaceutical i l t ( isolator (= grade A) d A) – The room should have a positive pressure … 40
H Hazardous drugs d d • Preparation under negative pressure, protecting operator and environment from contamination operator and environment from contamination, should only be used for the preparation of h hazardous pharmaceuticals (e.g. cytotoxic d h i l ( i drugs, d radiopharmaceuticals, … • Laminar Flow Cabinets (LFCs) are not suitable for the preparation of hazardous drugs Biohazard safety preparation of hazardous drugs. Biohazard safety cabinets (BSCs) should be used instead, with a vertical downward air flow vertical downward air flow …
41
E i Equipment t • Special requirements for aseptic preparation activities: – … the background environment for LFCs and BSCs should meet grade B requirements, with grade D required for meet grade B requirements, with grade D required for pharmaceutical isolators – Any justification yj for background environments of a lesser g grade should be based on a documented risk assessment which should be performed with great care. – Possible factors which could be considered in a risk assessment include: • Time between preparation and use • Use of a closed system • … 42
U Use of a closed system f l d t Closed Procedure (Glossery) (general definition ‘PIC/S’) • A procedure whereby a sterile pharmaceutical product is prepared by transferring sterile ingredients or solutions to a pre‐sterilised sealed container, either directly or using a sterile transfer container, either directly or using a sterile transfer device, without exposing the solution to the external environment
43
Cl thi Clothing • Grade C – Hair, arms and, where relevant, beard and moustache should be covered – A single or two‐piece trouser suit, gathered at the wrists and with high neck gathered at the wrists and with high neck and appropriate shoes or overshoes should be worn. h ld b – They should shed virtually no fibres or y y particulate matter. 44
Cl thi Clothing • Grade A/B – Headgear should totally enclose hair and, where should totally enclose hair and where relevant, beard and moustache; it should be tucked into the neck of the suit; a face‐mask tucked into the neck of the suit; a face mask should be worn to prevent the shedding of droplets – Appropriate sterilised, non‐powdered rubber or plastic gloves p g and sterilised or disinfected footwear should be worn – The protective clothing should shed virtually no p g y fibres or particulate matter and retain particles shed by the body 45
Cl thi Clothing • Outdoor clothing should not be brought into changing rooms leading to grade B changing rooms leading to grade B and C areas • For every worker in a grade A/B area, clean sterile (sterilised or adequately sanitised) protective garments should be provided at each working session. • Gloves should be regularly disinfected during operations during operations. 46
Cl Cleaning i • Clean areas should be regularly cleaned according to a documented and according to a documented and approved procedure • Cleaning and disinfecting agents should be free from viable micro organisms and g those used in Grade A and B areas should be sterile and spore free. should be sterile and spore free • For sterile alcohol sprays and other materials brought into clean areas an in l b h l i use expiry date should be defined 47
D Documentation t ti • Completed processing records should be retained for a sufficient period to satisfy legislative requirements a sufficient period to satisfy legislative requirements • In any case, records should be retained at least one year after the expiry date of the relevant finished p product • Procedures and preparation instructions (including prescriptions) should be retained for at least five prescriptions) should be retained for at least five years after their use
48
Aseptic Processing Aseptic Processing Key elements of the process • Maintaining the integrity of the aseptic processing area, and care of the workstation and its d f h k i di environment • Handling and preparation of starting materials, especially any disinfection processes especially any disinfection processes • Entry of materials into the processing area • Standard aseptic processing techniques, including not‐touching critical surfaces, correct positioning of g , p g materials within the laminar air flow, and use of specific pieces of equipment and regular sanitization specific pieces of equipment and regular sanitization 49 of gloves
Aseptic Processing Aseptic Processing Key elements of the process • Segregation and flow of materials to ensure no accidental cross contamination or mix up of accidental cross contamination or mix up of prescriptions or products • Removal of product and waste materials from the Removal of product and waste materials from the processing area. • All aseptic processing should be carried out by All i i h ld b i d b competent staff who are authorized to perform their work by the Responsible Person. kb h ibl • The number of people present in the room should be kept to a minimum 50
Aseptic Processing Aseptic Processing Key elements of the process • Only sterile materials should be taken into grade A or B areas e g settle plates swabs and cleaning or B areas e.g. settle plates, swabs, and cleaning materials. – Product solutions that are non sterile should be filtered through a sterile filter of nominal pore size of 0.22 micron ( (or less) before being taken into Grade A or B areas ) – When this is not possible, adequate decontamination measures should be taken
51
A ti P Aseptic Processing i • Process validation of aseptic procedures should be performed by using broth or a similar nutrient media performed by using broth or a similar nutrient media to simulate the aseptic procedure (media fills) and should be performed initially as well as subsequently h ld b f d i i i ll ll b l on a regular basis, … • The transfer of materials into the Grade A workstation is usually done by disinfection or workstation is usually done by disinfection or sanitisation rather than sterilisation
52
Q lit Quality control t l • If starting materials are themselves licensed medicinal products then it is not usually necessary medicinal products then it is not usually necessary to test these before use • If a product is prepared for a single patient, it is assumed that no end product testing will be p g required • The Responsible Person should ensure that the The Responsible Person should ensure that the testing laboratory has a comprehensive knowledge of microbiology and that quality assurance systems f b l d h li are regularly reviewed. Off‐site testing facilities should be regularly audited. 53
M it i Monitoring • The extent to which monitoring is performed should be defined and based upon a risk should be defined and based upon a risk assessment • Potential circumstances which may justify a reduced monitoring frequency (i.e. less often g q y( than recommended in this section) include: – – – –
Use of closed systems during preparation Use of closed systems during preparation Immediate use of prepared products Terminal sterilisation of products i l ili i f d Decrease of workload (less operational activities to be observed) 54
Cl ifi ti ‘ t t’ Classification ‘at rest’ Recommended frequencies for classification tests • Laminar flow cabinets (LFCs) / Biohazard Safety L i fl bi t (LFC ) / Bi h dS f t Cabinets (BSCs) Particle counts
Yearly
Room air changes per hour
Yearly
Air velocities on workstations
Yearly
HEPA filter integrity checks
Yearly 55
Cl ifi ti ‘ t t’ Classification ‘at rest’ Recommended frequencies for classification tests • Isolators I l t Isolator alarm functional tests
Yearly
Isolator leak test
Yearly
HEPA filter integrity checks
Yearly
56
Environmental monitoringg ‘in operation' Recommended frequencies of physical monitoring • Laminar flow cabinets (LFCs) / Biohazard Safety L i fl bi t (LFC ) / Bi h dS f t Cabinets (BSCs) Pressure differentials between rooms between rooms
Before beginning of work, usually daily usually daily
Pressure differentials across Pressure differentials across Before beginning of work, Before beginning of work HEPA filters (workstation) usually daily Particle counts
Quarterly in the operational state 57
Environmental monitoringg ‘in operation' Recommended frequencies of physical monitoring • Isolators I l t Pressure differentials across Before beginning of work, HEPA filters usually daily Isolator glove integrity
Visual checks every session
Isolator pressure hold test (with gloves attached)
Weekly
58
Environmental monitoringg ‘in operation' Recommended frequencies of microbiological monitoring Direct working environment (Grade A)
Background environment
Settle plates Settle plates
Every working session Every working session
Weekly
Glove finger dabs
At the end of each working session ki i
At the end of each working session ki i
Surface samples (swabs or contact plates)
Weekly
Monthly
Active air samples p
Quarterlyy
Quarterlyy 59
GUIDE TO GOOD PRACTICES FOR GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS GUIDELINES ON THE STANDARDS REQUIRED FOR THE REQUIRED FOR THE PREPARATION OF NON‐STERILE LIQUIDS, CREAMS AND OINTMENTS
60
Pi i l Principle • Liquids, creams and ointments may be particularly susceptible ti l l tibl to microbial and other t i bi l d th gp p contamination during preparation • Therefore special measures should be taken to prevent any contamination to prevent any contamination
61
P Premises i and Equipment dE i t • Closed systems for processing and transfer are recommended in order to protect the product d di d t t t th d t from contamination • Production areas where the product or open clean containers are exposed should normally l d h ld ll y with filtered air be effectively ventilated • Production areas should not be used for other activities 62
Measures to reduce the risk of contamination • The use of dedicated garments and hair covers • Sanitising critical surfaces before use with alcohol • If more than one activity is undertaken in the If more than one activity is undertaken in the production area at a time, … be adequate segregation ti to prevent cross contamination t t t i ti and mix‐ups. A risk assessment should be performed. 63
Measures to reduce the risk of contamination • The use of dedicated equipment is recommended for potent substances, d df t t bt penicillins, cephalosporins, sensitising p , p p , g agents, g , cytotoxics, and other substances that are very hazardous or difficult to clean hazardous or difficult to clean. • These materials should be identified • A risk assessment performed.
64
P Premises i and Equipment dE i t • The use of glass apparatus should be avoided wherever possible h ibl High quality stainless steel is often the stainless steel is often the • High quality material of choice for parts coming into contact with product h d Where glass equipment is used it should be • Where glass equipment is used, it should be checked for damage before and after use.
65
P d ti Production • The chemical and microbiological quality of water used in production should be t di d ti h ld b specified ifi d and monitored • Mixing and filling processes may require validation, and mixing times and speeds lid i d d d should be recorded • It is recommended that product is packaged as soon as possible (the same day) 66
P d ti Production • The extent to which physical, chemical and microbiological quality control tests are microbiological quality control tests are performed should be defined on basis of a risk assessment ik Expiry dates (use by dates) should be set and • Expiry dates (use by dates) should be set and justified for the unopened product • Once the container is opened, it may be O th t i i d it b necessary to recommend an in‐use expiry date 67
T k h Take home message • Good G d Manufacturing M f t i Practice P ti = – Risico‐analyse – Voorbereidingg – Documentatie
• Good Manufacturing Practice = – Specifieke manier van denken en werken – Investeringen in mensen en middelen – Samenwerking
• Good Manufacturing Practice = – Uitdaging voor ziekenhuisapothekers – Uitbouw ziekenhuisfarmacie
• KB 1885 (annex PIC/s) = – Geen vijand van de ziekenhuisapotheker Geen vijand van de ziekenhuisapotheker – Katalysator voor ziekenhuisfarmacie op Europees niveau
68
VRAGEN ? VRAGEN ?
69
